Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
MLLT3	rs10964552	AA + AC	cisplatin	efficacy	yes	This SNP was significantly associated with stage <pT2 (downstaging after neoadjuvant chemotherapy) in the discovery cohort, but not the replication cohort. This measurement was a secondary analysis.	Genotypes AA + AC are associated with decreased response to cisplatin in people with Urinary Bladder Neoplasms as compared to genotype CC.	27150640	1448112545
MLLT3	rs6475448	AA	montelukast	efficacy	yes	Patients who were homozygous for rs6475448 showed markedly increased mean d forced expiratory volume (FEV1) from baseline after 8 weeks of montelukast. The largest increase was observed for Leukotriene Modifier or Corticosteroid or Corticosteroid-Salmeterol (LOCCS); the rs6475448-AA genotype was associated with a LS-mean delta FEV1 of 344 mL vs. -4.66 mL for rs6475448-GG genotype. Study Cohort: Discovery cohort (N=133): American Lung Association Asthma Clinical Research Center (ALA-ACRC)-supported trials, the Leukotriene Modifier Or Corticosteroid or Corticosteroid-Salmeterol Trial (LOCCS) and Effectiveness of Low Dose Theophylline as Add On Therapy for the Treatment of Asthma (LODO) trials. Replication cohort (N=184): Childhood Asthma Research and Education (CARE) Network- Characterizing the Response to a LT Receptor Antagonist and an Inhaled Corticosteroid and Pediatric Asthma Controller Trial (CLIC and PACT)	Genotype AA is associated with increased response to montelukast in people with Asthma as compared to genotype GG.	26083242	1444929392